Purple Biotech (PPBT)

• Market cap: $7.52M
• 1 day: 13.15%
• 5 days: 14.98%
• 1 month: 1.43%
• 3 months: -19.77%
• 6 months: -32.06%
• Year to date: -38.13%
• 1 year: -98.37%
• 5 years: -99.82%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Employees: 7

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

40% more funds holding

Funds holding: 10 [Q3] → 14 (+4) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.03% less ownership

Funds ownership: 0.05% [Q3] → 0.02% (-0.03%) [Q4]

60% less capital invested

Capital invested by funds: $946K [Q3] → $378K (-$568K) [Q4]

79% less call options, than puts

Call options by funds: $35K | Put options by funds: $167K